Drug Availability Update
Further to DrugAlert 469, HPS Pharmacies wish to give notice that Pfizer Australia is continuing to experience a supply interruption for heparin as follows:
DBL™ Heparin Sodium Injection BP
Heparin sodium 5,000 IU/0.2mL
Supplies are expected to return to normal in mid-September 2019. An internationally registered brand of heparin sodium has been approved for supply under Section 19A of the Therapeutic Goods Act 1989. The packaging for this product is in the German language. Please refer to the Australian product information for DBL™ Heparin Sodium for further information when using this product.
Supply of heparin sodium under Section 19A is associated with a longer lead time as the product must be sourced internationally. This product is also significantly more expensive than the Australian registered product it replaces. Consideration of therapeutic alternatives such as a low molecular weight heparin (e.g. enoxaparin) may be preferred where clinically appropriate.
Retain this notice in a prominent position, including in other related business units until supplies return to normal. Report any problems identified with medicines, vaccines or medical devices to the TGA.
Should you require further information regarding this matter, please contact Pfizer Australia on 1800 629 921 or your pharmacist at HPS Pharmacies.